Seqirus USA Inc., a global biotechnology company, has been awarded a multiple-award Federal Supply Schedule (FSS) contract V797D70074 by the U.S. Department of Veterans Affairs (VA) to provide a range of influenza vaccines and pharmaceuticals. The contract, which is set under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, enables Seqirus to deliver a variety of influenza vaccine formulations and presentations, including multi-dose vials, pre-filled syringes, and specialized vaccines for...
This federal contract IDV award, SPE2DP25D0004, is a single-award Indefinite Delivery Contract valued at $6,857,675.50 and administered by the Defense Logistics Agency (DLA) Troop Support. The contract was awarded to Seqirus USA Inc., a foreign-owned, for-profit manufacturer of influenza vaccines. The contract aims to procure injectable, egg-free influenza vaccines for the 2025-2026 flu season, with an estimated annual quantity of 280,000 doses and a maximum of 150% of the annual estimate. The...
This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency Troop Support Medical to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $27.5M IDC, which has a period of performance through June 2019, aims to procure approximately 3.6 million doses of injectable influenza vaccine in multi-dose vials and pre-filled syringes for various ages, including pediatric formulations. The contract supports...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency's Medical Supply Chain unit to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development and delivery. The contract, valued at $36,120,112.50, aims to procure approximately 3.23 million doses of injectable influenza virus vaccines in multi-dose vials and pre-filled syringes for various age groups, including elderly, adult, and pediatric populations. The vaccines are intended...
The federal contract IDV being summarized is a multiple award Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc. for the delivery of adult influenza vaccines for the 2024-2025 flu season. The $215,741,000 IDC covers a range of influenza vaccine products and presentations, including multi-dose vials, pre-filled syringes, and specialized formulations for different age groups. Seqirus, a foreign-owned for-profit manufacturer,...
The Department of Veterans Affairs National Acquisition Center awarded an indefinite delivery contract to Seqirus USA Inc. to deliver influenza virus vaccines for the 2022-2023 season to the VA, Federal Bureau of Prisons, Indian Health Service, and James A. Lovell Federal Health Care Center. Task orders under the contract, with a potential value of $69,190,924.13, provide vaccines including 10-dose vials, single dose syringes in boxes of 10, and an adjuvant vaccine for individuals aged 65 and...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development and delivery. The $143 million IDC is for the supply of adult influenza vaccines, and a separate $208 million IDC is for pediatric influenza vaccines, to support the CDC's nationwide immunization programs from 2022-2023. Seqirus USA Inc. has also been awarded several other high-value...
The National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), has awarded a single-award Indefinite Delivery Contract (IDC) to Seqirus USA Inc. for the procurement of Influenza Virus Vaccines for the 2025-2026 flu season. The $51.6 million contract has a period of performance from March 15, 2025, to March 14, 2026, and will provide vaccines to the VA, State Veteran Homes, Bureau of Prisons, Indian Health Service, and Captain James A. Lovell Federal Health...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $410,587,500 multiple-award IDC covers the procurement of 2025-2026 pediatric flu vaccines for the federal government. As a registered federal contractor since 2008, Seqirus USA Inc. has extensive experience supplying influenza vaccines to various government...
The Centers for Disease Control and Prevention awarded Seqirus USA Inc. a multiple award indefinite delivery contract with a potential value of $129.8 million to supply pediatric influenza vaccines through February 2028. Task orders will be issued against the contract to procure required vaccines annually to support the CDC's national immunization programs. As a leading manufacturer of influenza vaccines, Seqirus will deliver various formulations of pediatric flu vaccines to the CDC for...